Efficiency of Monoclonal Antibodies Application against Covid-19
DOI:
https://doi.org/10.48112/acmr.v3i2.34Keywords:
New Coronavirus Infection, COVID-19, monoclonal antibodies, interleukin-6Abstract
Abstract Views: 33
Despite the 20 years history of pathogenic coronavirus infection, methods of prevention and treatment of diseases caused by this infection were not developed yet. One of the reasons could be the features of pathogenesis and a quick spread of the pandemic which may have made researches more complicated. As an inflammatory process develops, a generalization of infection also develops. A cytokine secretion becomes rockets up, Interferon-γ (IFN-y), interleukin-1(IL-1), interleukin-6 (IL-6), interleukin-12 (IL-12), concentration increases. To put it in other words, the primary inflammatory reaction enters a new phase — the cytokine storm phase. In this regard, adequate therapy aimed at stopping the uncontrolled process induced not so much by viremia as by the inflammation associated with it becomes crucial. Therefore, the aim of our research was to study the impact of monoclonal antibodies, in particular the drug "Kazirivimab + Imdevimab" — a combination of recombinant monoclonal antibodies aimed against S-protein on the clinical course and laboratory data in patients with a new coronavirus infection – Covid-19.
References
Hosseini A, Hashemi V, Shomali N, et al. Innate and adaptive immune responses against coronavirus. Biomed Pharmacother. 2020;132:110859. doi:10.1016/j.biopha.2020.110859
Loo YM, Gale M Jr. Immune signaling by RIG-I-like receptors. Immunity. 2011;34(5):680-692. doi:10.1016/j.immuni.2011.05.003
Aguiar JA, Tremblay BJ, Mansfield MJ, et al. Gene expression and in situ protein profiling of candidate SARS-CoV-2 receptors in human airway epithelial cells and lung tissue. Eur Respir J. 2020;56(3):2001123. doi:10.1183/13993003.01123-2020
Anastassopoulou C, Russo L, Tsakris A, Siettos C. Data-based analysis, modelling and forecasting of the COVID-19 outbreak. PLoS One. 2020;15(3):e0230405. doi: 10.1371/journal.pone.0230405.
Battegay M, Kuehl R, Tschudin-Sutter S, Hirsch HH, Widmer AF, Neher RA. 2019-novel Coronavirus (2019-nCoV): estimating the case fatality rate - a word of caution. Swiss Med Wkly. 2020;150:w20203. doi: 10.4414/smw.2020.20203.
Casadevall A, Pirofski LA. The convalescent sera option for containing COVID-19. J Clin Invest. 2020;130(4):1545-1548. doi: 10.1172/JCI138003.
Chen L, Xiong J, Bao L, Shi Y. Convalescent plasma as a potential therapy for COVID-19. Lancet Infect Dis. 2020;20(4):398-400. doi: 10.1016/S1473-3099(20)30141-9.
Cowling BJ, Park M, Fang VJ, Wu P, Leung GM, Wu JT. Preliminary epidemiological assessment of MERS-CoV outbreak in South Korea, May to June 2015. Euro Surveill. 2015;20(25):7-13. doi: 10.2807/1560-7917.es2015.20.25.21163.
Ablikim M, Achasov MN, Adlarson P, Ahmed S, Albrecht M, Amoroso A, et al. Direct Measurement of the Branching Fractions B(ψ(3686)→J/ψX) and B(ψ(3770)→J/ψX), and Observation of the State R(3760) in e^{+}e^{-}→J/ψX. Phys Rev Lett. 2021 Aug 20;127(8):082002. doi: 10.1103/PhysRevLett.127.082002
Guo YR, Cao QD, Hong ZS, Tan YY, Chen SD, Jin HJ, et al. The origin, transmission and clinical therapies on coronavirus disease 2019 (COVID-19) outbreak - an update on the status. Mil Med Res. 2020;7(1):11. doi: 10.1186/s40779-020-00240-0.
Huang X, Wei F, Hu L, Wen L, Chen K. Epidemiology and Clinical Characteristics of COVID-19. Arch Iran Med. 2020;23(4):268-271. doi: 10.34172/aim.2020.09.
Lai CC, Shih TP, Ko WC, Tang HJ, Hsueh PR. Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and coronavirus disease-2019 (COVID-19): The epidemic and the challenges. Int J Antimicrob Agents. 2020;55(3):105924. doi: 10.1016/j.ijantimicag.2020.105924.
Li X, Geng M, Peng Y, Meng L, Lu S. Molecular immune pathogenesis and diagnosis of COVID-19. J Pharm Anal. 2020;10(2):102-108. doi:10.1016/j.jpha.2020.03.001
Shanmugaraj B, Siriwattananon K, Wangkanont K, Phoolcharoen W. Perspectives on monoclonal antibody therapy as potential therapeutic intervention for Coronavirus disease-19 (COVID-19). Asian Pac J Allergy Immunol. 2020;38(1):10-18. doi: 10.12932/AP-200220-0773.
Sohrabi C, Alsafi Z, O'Neill N, Khan M, Kerwan A, Al-Jabir A, et al World Health Organization declares global emergency: A review of the 2019 novel coronavirus (COVID-19). Int J Surg. 2020;76:71-76. doi: 10.1016/j.ijsu.2020.02.034.
Velavan TP, Meyer CG. The COVID-19 epidemic. Trop Med Int Health. 2020;25(3):278-280. doi: 10.1111/tmi.13383.
Wang C, Li W, Drabek D, et al. A human monoclonal antibody blocking SARS-CoV-2 infection. Nat Commun. 2020;11(1):2251. doi:10.1038/s41467-020-16256-y
Yin S, Huang M, Li D, Tang N. Difference of coagulation features between severe pneumonia induced by SARS-CoV2 and non-SARS CoV2. J Thromb Thrombolysis. 2021;51(4):1107-1110. doi: 10.1007/s11239-020-02105-8.
Zhang W, Zhao Y, Zhang F, Wang Q, Li T, Liu Z, et al. The use of anti inflammatory drugs in the treatment of people with severe coronavirus disease 2019 (COVID-19): The Perspectives of clinical immunologists from China. Clin Immunol. 2020;214:108393. doi: 10.1016/j.clim.2020.108393.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2022 Advances in Clinical Medical Research
This work is licensed under a Creative Commons Attribution 4.0 International License.
OAI-PMH 
